Difference between revisions of "Talazoparib (Talzenna)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 20: | Line 20: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
| + | [[Category:Pfizer product]] | ||
Revision as of 00:44, 9 May 2021
Mechanism of action
PARP inhibitor
Diseases for which it is used
History of changes in FDA indication
- 10/16/2018: Initial approval for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. (Based on EMBRACA)
Also known as
- Code name: BMN-673
- Brand name: Talzenna